Prolia works well for osteoporosis. But stopping it — for any reason — without a transition plan carries a documented risk of rapid bone loss and spontaneous vertebral fractures. Many patients are started on Prolia without being told this. This page explains what happens after you stop, who's at risk, and what your doctor should do about it.
Prolia (denosumab) is a RANKL inhibitor — a biologic drug, not a bisphosphonate. RANKL is a protein that drives osteoclast activity (bone breakdown). Prolia blocks it, so while the drug is in your system, bone turnover slows significantly and bone density increases.
The critical difference from bisphosphonates is what happens when the drug clears. Bisphosphonates — like alendronate — bind directly to the mineral in your bone. Even after you stop taking them, there's a reservoir in the skeleton that continues releasing drug and suppressing bone breakdown for months to years. That's why a planned bisphosphonate drug holiday is feasible for appropriate patients.
Prolia doesn't accumulate in bone at all. It has a half-life in the body of roughly 25–28 days. Once the drug clears — which happens within months of your last injection — the RANKL signal is no longer blocked. Osteoclast activity doesn't just return to baseline; it rebounds sharply.
The rebound effect is a post-discontinuation surge in bone resorption that overshoots the pre-treatment baseline. Bone turnover markers (NTX, CTX) can spike to two or three times normal within 6–12 months of the last injection. BMD can fall rapidly — losing most of the gains from years of Prolia treatment within 12–18 months of stopping.
That rapid bone loss translates directly to fracture risk. A study published in PMC5915244 found increased vertebral fracture risk as soon as 8 months after Prolia discontinuation. A 2025 PubMed analysis (PMID 40057981) confirmed: "rebound increase in bone turnover, loss of BMD gains, and spontaneous vertebral fractures" are documented consequences. A comparative study in ScienceDirect (November 2024) found that denosumab discontinuation carries higher fracture risk than stopping any other class of osteoporosis medication.
Multiple vertebral fractures can occur simultaneously — a presentation that is genuinely unusual outside of severe trauma. For patients who had very low bone density before starting Prolia, the fracture risk during rebound can be severe.
This is where patients get caught off guard. You don't need to make an active decision to stop. These situations all trigger the rebound:
Based on current evidence, the rebound fracture risk window is roughly 8–16 months after the last Prolia injection. The peak appears to be around month 8–12. This is not a theoretical risk — case reports and clinical studies document patients fracturing multiple vertebrae with minimal or no trauma during this window.
| Time After Last Injection | What's Happening |
|---|---|
| 0–3 months | Drug still clearing; bone turnover starting to rise |
| 3–6 months | Bone resorption markers rising; BMD loss beginning |
| 6–12 months | Peak rebound; highest fracture risk window |
| 12–18 months | Rebound moderating but BMD loss continues |
| 18+ months | BMD stabilizes at a lower level without intervention |
The good news is that this risk is largely preventable. The key is starting a bisphosphonate before Prolia clears the system — bridging the transition so bone turnover never gets the chance to rebound.
A study published in PubMed (PMID 39448137) found that sequential bisphosphonate therapy after Prolia discontinuation substantially reduces rebound fracture risk. The current standard approach:
The timing matters. Starting too early (while Prolia is still active) doesn't help. Starting too late means bone has already been lost. Your doctor should have a specific date in mind for starting the bisphosphonate, based on your last injection date.
IV zoledronic acid (Aclasta) is sometimes preferred over oral alendronate for the transition because it can be given as a single infusion — removing the compliance issue of weekly pills. Some specialists use it as the default transition therapy after long-term Prolia use. It's covered under most provincial drug plans when oral bisphosphonates have failed or aren't tolerated, and many rheumatologists and endocrinologists use it routinely for Prolia transitions.
Not everyone who stops Prolia will fracture. But risk is higher for patients who:
Patients on Prolia for glucocorticoid-induced osteoporosis are in a particularly vulnerable position — the steroid continues to damage bone while the protective Prolia effect disappears. If you're on long-term prednisone and considering stopping Prolia, that conversation needs to involve your rheumatologist, not just your GP.
Prolia costs approximately $800–$1,000/year in Canada (two $400–$500 injections). It requires special authorization on most provincial drug plans — Ontario ODB, BC PharmaCare, and Alberta's Drug Benefit List all cover it with criteria. The authorization typically needs renewal, and if it lapses between injections, you could face a gap.
If your coverage is at risk of lapsing, don't just miss the injection. Call your doctor's office as soon as you know — there is usually time to arrange either a bridge or a transition plan. Do not stop cold because the paperwork didn't come through.
For patients who lose coverage entirely, Amgen (Prolia's manufacturer) has a Canadian patient support program. Ask your prescribing physician or pharmacist for a referral. Shoppers Drug Mart specialty pharmacy and other specialty dispensaries can also connect patients with manufacturer assistance programs.
Before starting Prolia:
Before stopping or pausing Prolia:
If your doctor is unfamiliar with the Prolia rebound issue, it may be worth asking for a referral to an endocrinologist or rheumatologist who specializes in metabolic bone disease. Academic centres in Vancouver (VGH), Toronto (St. Michael's, Sunnybrook), and Calgary all have dedicated osteoporosis clinics that manage these transitions regularly.
The FRAX-based fracture risk calculator gives you a baseline for thinking about your 10-year fracture probability. It won't capture the specific rebound risk from Prolia discontinuation, but it provides useful context for your conversation with your doctor.
For a broader picture of the medications available and how they compare, see the osteoporosis medications overview. If you've been on bisphosphonates and are wondering about a drug holiday (which is an entirely different situation), see bisphosphonate drug holiday: when to stop Fosamax or alendronate.